) is a Ser/Thr kinase implicated in a wide variety of cellular responses. PKD1 activation is generally attributed to a PKC-dependent pathway that leads to phosphorylation of the activation loop at Ser 744 /Ser 748 . This modification increases catalytic activity, including that toward an autophosphorylation site (Ser 916 ) in a postsynaptic density-95/disks large/zonula occludens-1 (PDZ)-binding motif at the extreme COOH terminus. However, there is growing evidence that PKD1 activation can also result from a PKC-independent autocatalytic reaction at Ser 744 /Ser 748 and that certain stimuli increase in PKD1 phosphorylation at Ser 744 /S 748 without an increase in autophosphorylation at Ser 916 . This study exposes a mechanism that results in a discrepancy between PKD1 COOH-terminal autocatalytic activity and activity toward other substrates. We show that PKD1 constructs harboring COOH-terminal epitope tags display high levels of in vitro activation loop autocatalytic activity and activity toward syntide-2 (a peptide substrate), but no Ser 916 autocatalytic activity. Cell-based studies show that the COOH-terminal tag, adjacent to PKD1's PDZ1-binding motif, does not grossly influence PKD1 partitioning between soluble and particulate fractions in resting cells or PKD1 translocation to the particulate fraction following treatment with PMA. However, a COOH-terminal tag that confers a high level of activation loop autocatalytic activity decreases the PKC requirement for agonistdependent PKD1 activation in cells. The recognition that COOHterminal tags alter PKD1's pharmacological profile is important from a technical standpoint. The altered dynamics and activation mechanisms for COOH-terminal-tagged PKD1 enzymes also could model the signaling properties of localized pools of enzyme anchored through the COOH terminus to PDZ domain-containing scaffolding proteins.
PROTEIN KINASE D1 (PKD1/) is the founding member of a family of Ser/Thr kinases (PKD1/, PKD2, and PKD3/) that play key roles in cell growth, apoptosis, adhesion, motility, and angiogenesis (9, 14) . PKD isoforms share a similar structural architecture consisting of an NH 2 -terminal C1 domain that binds lipids (diacylglycerol or phorbol esters), an autoinhibitory PH domain, and a COOH-terminal catalytic domain. PKD1 activation typically is attributed to receptor-dependent pathways that promote diacylglycerol accumulation and colocalize allosterically activated PKD1 with novel PKC (nPKC) isoforms at lipid membranes. nPKCs then trans-phosphorylate PKD1 at Ser 744 /Ser 748 [2 highly conserved Ser residues in the activation loop of the kinase domain (nomenclature based on rodent sequence)], leading to an increase in catalytic activity. PKD1 activation then leads to an increase in autophosphorylation at Ser 916 , a site that resides in a postsynaptic density-95/disks large/zonula occludens-1 (PDZ)-binding motif at the extreme COOH terminus of the enzyme. Autophosphorylation at Ser 916 reverses binding to PDZ domain-containing scaffolding proteins, limiting the duration and amplitude of localized PKD signaling responses.
PKD1 activation can also result from activation loop Ser 744 / Ser 748 autophosphorylation when nPKCs are downregulated (10, 12) . We recently demonstrated that PKD1 autophosphorylates at Ser 748 only following a prior priming autophosphorylation at Ser 916 ; the Ser 748 autophosphorylation reaction is abrogated by a S916A substitution (10) . However, the PKD1-S916A mutant remains active as a kinase. PKD1-S916A autophosphorylates at Ser 744 , and it displays a high level of activity toward heterologous protein and peptide substrates. These results emphasize two generally underappreciated aspects of the control of PKD1 activity. (16) . A mechanism that might account for a discrepancy between PKD1 activity toward heterologous protein substrates vs. its COOH-terminal autocatalytic site has never been obvious. This study identifies for the first time a condition that generates a catalytically active form of PKD1 that does not autophosphorylate at Ser 916 . PKD1 mutants. Plasmids that drive expression of HA-tagged wildtype (WT)-PKD1 and PKD1-S916A generated by the Toker laboratory were obtained from Addgene. A plasmid that drives expression of full-length PKD1 with GFP fused to the COOH terminus was generously provided by Drs. David E. Clapham and Elena Oancea (6) . WT-PKD1 and PKD1-S916A constructs with a FLAG tag fused to the COOH terminus were generated by PCR and validated by sequencing. PKD1 expression plasmids were introduced into human embryonic kidney (HEK 293) cells by Effectene transfection reagent (Qiagen) according to the instruction manual. Cells were grown for 24 h and lysed in RIPA buffer containing 1 mM sodium orthovanadate, 10 g/ml aprotinin, 10 g/ml leupeptin, 10 g/ml benzamidine, 0.5 mM PMSF, 5 M pepstatin A, and 0.1 M calyculin. Cell extracts were used for immunoblotting experiments or subjected to immunoprecipitation with anti-HA (Roche Applied Science), mouse monoclonal anti-GFP 3E6 (Invitrogen), or anti-FLAG (Sigma) for subsequent in vitro kinase assays.
MATERIALS AND METHODS

Materials
In vitro kinase assays. In vitro kinase assays were performed with PKD1 immunoprecipitated from 150 mg of starting cell extract. Incubations were performed in 110 l of a reaction buffer containing 30 mM Tris-Cl, pH 7. (2)]. Figures 1-3 show results of a single gel exposed for a uniform duration. In Figs. 2 and 3, the dividing lines, or white spaces, denote a rearrangement of data from different regions of a single gel (to eliminate extraneous data included in the original experiment that is tangential to issues examined in this study).
Syntide-2 kinase assays were performed in a similar manner, with 0.36 mg/ml syntide-2 included as the PKD1 substrate. Assays were terminated by addition of 30 l of 350 mM phosphoric acid followed by centrifugation at 14,000 g for 10 min. Fifty microliters of each supernatant were spotted onto phosphocellulose filter papers (P-81), which were dropped into 75 mM phosphoric acid, washed (3 times for 5 min), dried, and counted for radioactivity.
RESULTS
Current concepts regarding the molecular determinants that control PKD1 activity are based largely on studies that interrogate the biochemical properties and cellular actions of epitope-tagged PKD1 mutants. The general approach has been to use GFP (or red fluorescent protein)-tagged enzymes to visualize dynamic changes in the subcellular distribution of the enzyme in agonist-stimulated cells or HA-tagged constructs to examine the in vitro biochemical properties of the enzyme; the HA tag provides a particularly convenient handle to purify the enzyme and avoid contamination with endogenous kinases. The general consensus of these studies is that epitope tags do not detectably alter the phorbol ester-binding affinity, activation loop phosphorylation, or catalytic activity of the enzyme (5, 8, 18) .
In this context, Fig. 1 shows a heretofore unrecognized difference in the phosphorylation profiles and catalytic activities of NH 2 -terminal (HA)-tagged vs. COOH-terminal (FLAG or GFP)-tagged PKD1 enzymes. The NH 2 -terminal HA-tagged enzyme is recovered from resting HEK 293 cells with littleto-no activation loop or Ser 916 phosphorylation; autophosphorylation at both activation loop sites and the COOH terminus increases upon treatment with PMA (Fig. 1) . HA-PKD1-Ser 916 autophosphorylation is a very rapid reaction that is completed within the first 5 min of incubation (Fig. 1B) (17) ]. Autophosphorylation at these other sites contributes to 32 P incorporation but is not detected in the Western blot studies. Kinetic studies show that the COOH-terminal tag accelerates the kinetics and amplitude of PKD1 autophosphorylation and PKD1-dependent phosphorylation of syntide-2 relative to the NH 2 -terminal HA-tagged enzyme. PKD1-FLAG also displayed increased activity toward the endogenous protein substrate cAMP response element-binding protein (3.1 Ϯ 0.2-fold vs. HA-PKD1, n ϭ 5, P Ͻ 0.05), which is a physiologically relevant substrate of PKD (7, 12) . However, COOHtagged PKD1-FLAG or PKD1-GFP enzymes do not autophosphorylate at Ser 916 , even with prolonged (up to 60 min) incubation intervals.
We previously demonstrated that a S916A substitution in the NH 2 -terminal HA-tagged enzyme disrupts Ser 748 autocatalytic activity (10) . This phenotype (which is reproduced in Fig. 2A ) is in marked contrast to the phenotype of the COOH-terminaltagged enzyme, where a Ser 916 autophosphorylation defect does not prevent activation loop autophosphorylation at Ser 748 . In theory, this discrepancy might be due to an artifact if a COOH-terminal tag interferes with immunodetection of adjacent sequence at the COOH terminus of the enzyme. This trivial explanation is effectively countered by the observation that the PKD1-FLAG enzyme is readily detected by an antibody that recognizes sequence at the COOH terminus of PKD1 ( Figs. 1 and 2) . A previous study showed that a COOHterminal-directed PKD1 antibody also recognizes PKD1-GFP (1). The trivial explanation also is refuted by additional experiments showing that a S916A substitution in the PKD1-FLAG backbone does not abrogate Ser 748 autophosphorylation (Fig.  2B) . Collectively, these results argue that a COOH-terminal epitope results in a bone fide Ser 916 autophosphorylation defect that does not disrupt Ser 748 autocatalytic activity. We performed cell fractionation studies to determine whether a COOH-terminal tag, adjacent to the PDZ1-binding motif, influences PKD1 translocation to particulate membranes. Figure 3A shows that HA-PKD1 and PKD1-FLAG enzymes partition similarly between soluble and particulate fractions in resting cells and that both enzymes are detected exclusively in the particulate fraction following treatment with PMA. These subcellular localization patterns for HA-PKD1 and PKD1-FLAG enzymes recapitulate the subcellular partitioning patterns described for native PKD1, indicating that epitope tags do not grossly alter subcellular localization patterns of the enzyme. Figure 3B shows that PMA treatment leads to increased Ser 744 /Ser 748 phosphorylation on HA-PKD1 and PKD1-FLAG enzymes, but the PMA-dependent increase in Ser 916 phosphor- ylation is confined to HA-PKD1; no PMA-treated PKD1-FLAG-Ser 916 phosphorylation could be detected. These results indicate that the COOH tag-induced PKD1-Ser 916 autophosphorylation defect identified in the in vitro studies is retained in an in vivo context. Finally, we identified an effect of the COOH tag on the mechanism for PKD1 activation. Figure 3C shows that thrombin (an agonist for the endogenous G protein-dependent protease-activated receptor) induces a robust increase in HA-PKD1-Ser 744 /Ser 748 phosphorylation; this response is mediated by a PKC-dependent pathway that is inhibited by GF109203X. In contrast, the thrombin-dependent increase in Ser 744 /Ser 748 phosphorylation on the PKD1-FLAG enzyme (which already displays some constitutive Ser 744 /Ser 748 phosphorylation in resting cells) is via a PKC-independent mechanism that is not inhibited by GF109203X. Since the GF109203X pretreatment protocol used in our studies effectively inhibits PKC activity (11), these results argue that a COOH-terminal epitope (which confers a high level of activation loop autocatalytic activity) impacts on the PKC requirement for agonist-dependent PKD1 activation in cells.
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DISCUSSION
In the 20 years since PKD1 was first identified as a lipidactivated signaling kinase, it has been implicated in a wide range of fundamental biological processes that regulate cell proliferation, differentiation, apoptosis, immune regulation, cardiac contraction, cardiac hypertrophy, angiogenesis, and cancer (9, 14) . The emergence of PKD1 as a mediator of various physiological and pathological cellular responses has driven efforts to understand the mechanisms underlying PKD1's cellular actions and, particularly, the regulatory phosphorylations that control PKD1 activity. Our current understanding of the regulatory phosphorylation that accompanies (or is required for) PKD1 activation is based largely on studies with heterologously overexpressed WT or mutant PKD1 enzymes harboring epitope tags. Most studies have used PKD1 vectors containing an epitope tag (HA, GFP, or cMyc) at the NH 2 terminus. There is considerable evidence that PKD1 tolerates epitope tags at its NH 2 terminus; NH 2 -terminal epitope tags do not grossly influence PKD1 translocation or agonist-dependent changes in PKD1 phosphorylation (13, 17) . The experience with PKD1 constructs harboring a COOHterminal tag is considerably more limited. Previous studies used PKD1-GFP primarily to track PKD1 localization and signaling responses in specific subcellular compartments (2, 6) . A comprehensive analysis of the possible confounding effects of the COOH-terminal epitope tag has not been published. This study identifies two major effects of a COOH-terminal epitope tag: we show that 1) PKD1-GFP and PKD1-FLAG enzymes exhibit a PKD1-Ser 916 autophosphorylation defect, exposing a condition that results in an agonist-dependent increase in PKD1 catalytic activity that is not accompanied by an increase in PKD1-Ser 916 phosphorylation and 2) the COOH-terminaltagged enzymes display enhanced activation loop autophosphorylation and increased syntide-2 kinase activity (compared with HA-PKD1). The similar results for COOH-terminal GFPand FLAG-tagged enzymes indicate that it is the location, rather than the identity of the tag, that is the factor. The coordinate changes in activation loop and Ser 916 phosphorylation are presumed to be the direct consequence of the tag at the COOH terminus. However, more elaborate regulatory controls that arise through indirect mechanisms (e.g., a conformational change due to autophosphorylation at one site leading to a change in autocatalytic activity toward another site in the enzyme) are possible and might be considered in future studies.
The identification of an altered pharmacological profile for a COOH-terminal-tagged PKD1 enzyme is important from a technical standpoint. A COOH-terminal epitope tag is predicted to induce a similar change in the pharmacological profile of PKD2 (which is structurally similar to PKD1). Effects on PKD3 are less predictable, since PKD3 lacks the conserved COOH-terminal autophosphorylation site and PDZ-binding motif; this structural difference between the extreme COOHterminal regions of PKD2 and PKD3 has been implicated in their distinct subcellular localization patterns (7) . The relevance of these findings to the control of other enzyme families is uncertain. While structural determinants at the COOH terminus of AGC protein kinases (e.g., PKA, PKC, and AKT) function as essential components (or key allosteric regulators) of the kinase machinery (3) and there is evidence that the extreme COOH terminus is critical for the catalytic competence and biological functions of several PKC family enzymes (15, 19 -21) , studies to date indicate that COOH-terminal tags do not grossly alter the regulatory controls for PKC␦. Some COOH-terminal tags are well tolerated.
Finally, it is tempting to speculate that PKD1 constructs harboring a COOH-terminal epitope might model a pool of enzyme that is anchored via its COOH-terminal PDZ domaininteracting motif to a PDZ domain-containing scaffolding protein. Kunkel ulatory factor 1 (NHERF-1). By using a series of genetically encoded PKD activity reporters, these investigators showed that the dynamics of agonist-dependent PKD1 activation at the membrane-localized NHERF-1 scaffold is markedly accelerated compared with PKD activation in other cellular compartments (4). Such accelerated activation kinetics for the PDZ-1-interacting domain-anchored enzyme were attributed to PKD1 colocalization with its activator PKC␦ at the NHERF-1 scaffold. While the notion that NHERF-1 functions as a platform to colocalize PKD1 with PKC␦ is quite reasonable, previous studies did not provide direct evidence that the accelerated activation kinetics for NHERF-1-associated PKD require PKC activity. In this regard, our studies suggest an alternative mechanism, namely, that PKD1's COOH terminus imposes a structural constraint that functions to limit PKD1's intrinsic catalytic activity and that a protein-protein interaction involving the COOH terminus (either the introduction of a COOH-terminal epitope or a docking interaction involving the COOH-terminal PDZ-binding domain) results in a conformation change that relieves this autoinhibitory constraint and increases PKD1's intrinsic catalytic activity. A catalytically active PKD1 that autophosphorylates at the activation loop would have a decreased requirement for PKC.
Collectively, these studies provide evidence that molecular determinants at the extreme COOH terminus of PKD1 function as regulators, and not just passive markers, of PKD1 activity, suggesting that structural determinants at the COOH terminus can be targeted for therapeutic advantage.
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